Alembic Ltd

Alembic Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Alembic Ltd

₹ 142 1.21%
22 Jul - close price
alembiclimited.com BSE: 506235 NSE: ALEMBICLTD
About

Alembic Limited is engaged in the businesses of Pharmaceuticals, Real Estate, and Power Assets. The company was started in 1907 as the flagship company of the Alembic Group. In 2010, the company demerged its core pharmaceutical business (formulations) into a wholly-owned subsidiary, Alembic Pharma Ltd and after the demerger, APL became the flagship company of the Alembic Group.
With its registered office in Vadodra, Alembic Ltd currently holds a 28.41% stake in Alembic Pharma Ltd and a 19.01% stake in another group entity Paushak Limited.[1]

Key Points

Business Portfolio:
A) Pharmaceuticals:
The company deals in the bulk drugs manufacturing and marketing of APIs like Estolate, Biphenyl Valine Oxalate, Venlafaxine, etc. AL is also engaged in R&D activity. [1]

Website BSE NSE
  • Market Cap ₹ 3,633 Cr.
  • Current Price ₹ 142
  • High / Low ₹ 156 / 74.2
  • Stock P/E 13.6
  • Book Value ₹ 85.1
  • Dividend Yield 1.70 %
  • ROCE 4.81 %
  • ROE 12.6 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 24.5%
  • Debtor days have improved from 61.4 to 45.8 days.
  • Company's working capital requirements have reduced from 141 days to 81.2 days

Cons

  • Tax rate seems low
  • Company has a low return on equity of 10.0% over last 3 years.
  • Earnings include an other income of Rs.54.8 Cr.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Realty Industry: Construction

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
29 21 20 19 18 22 37 31 37 37 32 39 49
25 17 17 16 15 17 26 20 24 26 22 28 25
Operating Profit 4 4 3 4 3 5 11 10 13 11 10 12 24
OPM % 14% 20% 15% 19% 16% 25% 30% 34% 36% 30% 31% 30% 49%
2 2 81 2 4 1 59 2 -9 3 48 2 2
Interest 0 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 1 1 1 1 1 2 2 2 2 2 2 3 1
Profit before tax 5 5 83 4 6 4 68 11 3 12 56 11 24
Tax % 21% 20% 11% 4% 20% 11% 10% 2% -55% 14% 8% 9% 12%
72 49 120 52 1 -19 115 46 48 44 91 61 72
EPS in Rs 2.80 1.91 4.68 2.02 0.04 -0.72 4.49 1.78 1.88 1.73 3.53 2.39 2.81
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2009 Mar 2010 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
1,099 1,121 144 134 147 125 124 74 74 78 127 157
1,016 1,018 134 128 140 114 106 71 62 64 87 101
Operating Profit 83 103 10 6 7 11 18 3 11 14 40 57
OPM % 8% 9% 7% 5% 5% 9% 15% 4% 15% 18% 32% 36%
7 16 21 25 25 37 29 93 10 89 54 55
Interest 42 32 1 0 0 0 0 0 0 0 0 1
Depreciation 38 43 6 6 5 4 3 3 4 5 7 8
Profit before tax 9 44 23 25 27 44 45 93 17 98 87 103
Tax % -19% 10% -3% 2% -3% 5% 8% 0% 19% 12% 7% 10%
11 40 107 235 145 163 213 329 343 222 191 269
EPS in Rs 0.39 1.48 3.99 8.78 5.45 6.10 8.30 12.82 13.35 8.65 7.42 10.46
Dividend Payout % 51% 17% 4% 2% 4% 3% 2% 5% 2% 21% 30% 23%
Compounded Sales Growth
10 Years: %
5 Years: 5%
3 Years: 29%
TTM: 24%
Compounded Profit Growth
10 Years: %
5 Years: 5%
3 Years: -8%
TTM: 35%
Stock Price CAGR
10 Years: 21%
5 Years: 32%
3 Years: 3%
1 Year: 81%
Return on Equity
10 Years: %
5 Years: 14%
3 Years: 10%
Last Year: 13%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2009 Mar 2010 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity Capital 27 27 53 53 53 53 51 51 51 51 51 51
Reserves 304 311 474 750 858 1,032 1,157 1,367 2,246 2,445 2,027 2,134
475 408 0 9 0 0 0 0 0 0 0 9
209 251 91 64 81 73 57 53 112 135 127 134
Total Liabilities 1,015 997 619 875 992 1,159 1,266 1,471 2,409 2,632 2,205 2,329
405 393 169 146 171 179 209 225 265 297 321 369
CWIP 7 4 2 0 0 0 0 3 6 0 0 1
Investments 8 8 299 605 732 913 1,001 1,133 2,047 2,208 1,754 1,786
595 591 149 124 89 67 55 110 91 127 130 173
Total Assets 1,015 997 619 875 992 1,159 1,266 1,471 2,409 2,632 2,205 2,329

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2009 Mar 2010 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
123 149 22 10 52 24 22 7 -2 -18 39 23
-56 -24 5 -5 -47 -22 68 57 -35 19 7 26
-70 -118 -25 -5 -5 -3 -89 -6 -15 -6 -46 -48
Net Cash Flow -2 7 2 -0 -0 -1 1 57 -52 -5 -0 0

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2009 Mar 2010 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 71 63 122 76 54 74 40 44 69 71 67 46
Inventory Days 158 158 880 659 438 247 289 411 2,112 2,885 3,694
Days Payable 112 128 200 144 128 125 202 151 693 640 1,237
Cash Conversion Cycle 117 93 801 591 364 195 126 305 1,488 2,316 67 2,502
Working Capital Days 125 108 235 172 39 20 13 22 98 223 118 81
ROCE % 7% 10% 4% 4% 4% 4% 7% 1% 4% 4% 5%

Shareholding Pattern

Numbers in percentages

2 Recently
Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024
70.88% 70.88% 70.88% 70.88% 70.88% 70.88% 70.88% 70.88% 70.88% 70.88% 70.88% 70.88%
1.23% 1.19% 1.12% 1.08% 0.83% 0.82% 0.70% 0.72% 0.85% 0.89% 1.07% 1.42%
4.89% 5.17% 4.69% 4.29% 4.12% 3.94% 3.94% 3.93% 3.40% 0.04% 0.04% 0.04%
23.00% 22.76% 23.31% 23.75% 24.16% 24.34% 24.48% 24.46% 24.87% 28.17% 28.02% 27.66%
No. of Shareholders 80,56178,38180,13583,00683,61283,63082,33981,73282,94794,01299,13098,478

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings